drugset

drugset / Trial / NCT01048255

Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

NCT01048255 ↗

Phase 2 Completed 60 enrolled Vertex Pharmaceuticals Incorporated

RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of VX-765 in subjects with Treatment-resistant Partial Epilepsy

Timeline

Start: 2010-01
Primary completion: 2010-11
Completion: 2010-11

Publications

Panebianco M, Walker L, Marson AG. Immunomodulatory interventions for focal epilepsy. Cochrane Database Syst Rev. 2023 Oct 16;10(10):CD009945. doi: 10.1002/14651858.CD009945.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Belnacasan	Small molecule	900 mg	Oral

Indications